Xeljanz XR FDA Approval History
Last updated by Judith Stewart, BPharm on Dec 14, 2021.
FDA Approved: Yes (First approved February 23, 2016)
Brand name: Xeljanz XR
Generic name: tofacitinib
Dosage form: Extended-Release Tablets
Company: Pfizer Inc.
Treatment for: Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis, Ankylosing Spondylitis
Xeljanz XR (tofacitinib) is a Janus kinase (JAK) inhibitor indicated for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis.
Development timeline for Xeljanz XR
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.